AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00755417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin Extended-Release (G-ER) 1800 mg
Description: G-ER 1800 mg daily dosage given as one 600-mg tablet in the morning and two 600-mg tablets in the evening.
Study NCT00755417 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo dosages of 1200 mg daily (two 600-mg tablets) and 1800 mg daily (one 600-mg tablet in the morning and two 600-mg tablets in the evening).
Study NCT02676843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-AV-1451
Description: A single injection of up to 10 millicuries of 18F-AV-1451 will be administered to subjects, followed by a 20-minute PET scan.
Study NCT04056793 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimized birthing position
Description: The parturients will be asked to adopt a supine position with a hyperflexion of the thighs and a flat back, and to maintain the position for a duration of twenty minutes.
Study NCT04823806 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spermidine (spermidineLIFE ®) OR Placebo
Description: 21 day of 6mg spermidine OR Placebo supplementation per day
Study NCT04321941 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lumentin
Description: Contrast agent used in combination with CTE
Study NCT04321941 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Movprep
Description: Contrast agent used in combination with MRE
Study NCT01628692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Tablets, oral, 30 mg, once daily
Study NCT04536298 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D
Description: Vitamin D softgel capsules; each capsule contains 3200 IU of vitamin D3. Three capsules per day (9600 IU/day) will be taken on days 1 and 2, and one capsule per day (3200 IU/day) will be taken on days 3 through 28
Study NCT04536298 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo softgel capsules. Three capsules per day will be taken on days 1 and 2, and one capsule per day will be taken on days 3 through 28
Study NCT01533688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Golytely (polyethylene glycol electrolyte lavage solution) and placebo
Description: 4 liters of polyethylene glycol electrolyte lavage solution (PEG-ELS-(GoLytely))+ placebo given the evening prior to the colonoscopy
Study NCT01533688 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: split dose of Golytely (polyethylene glycol electrolyte lavage solution) + placebo
Description: split dose (2 L taken the evening before and 2 L taken the morning of the colonoscopy) of 4 liters Golytely + placebo
Study NCT01533688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: split dose of Golytely (polyethylene glycol electrolyte lavage solution) and bisacodyl
Description: split dose ( 2 L taken the evening before and 2 L taken the morning of the colonoscopy) of 4 liters of Golytely + bisacodyl 10 mg
Study NCT01741350 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-friendly Health Recovery Program
Description: Four weekly HIV risk-reduction groups and routine clinical services (i.e., daily methadone and case management).
Study NCT01741350 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Time-and-Attention-Matched Control Condition
Description: Four weekly support groups and routine clinical services (i.e., daily methadone and case management).
Study NCT04010084 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Low level laser therapy
Description: The irradiation will be applied transcutaneously in the sublingual region (3 points on the left side and 3 points on the right side), irradiated for 30 seconds and the total treatment time will be 3 minutes. The group will receive irradiation with a DMC-branded laser EC device, with combined wavelength (660 and 780 nm), 1J of energy per point and output power of 35 mW. A disposable plastic material covering the application pen will be used for hygiene reasons.~The treatment will be performed twice weekly for a total of 4 consecutive weeks of treatment, and after completion, the patients will be reassessed of all the complementary tests that have been requested.
Study NCT04010084 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: The irradiation will be applied transcutaneously in the sublingual region (3 points on the left side and 3 points on the right side), irradiated for 30 seconds and the total treatment time will be 3 minutes. The group will receive placebo (with switched-off) irradiation of the DMC-brand laser therapy EC model, with combined wavelength (660 and 780 nm), 1J of energy per point and output power of 35 mW. A disposable plastic material covering the application pen will be used for hygiene reasons.~The treatment will be performed twice weekly for a total of 4 consecutive weeks of treatment, and after completion, the patients will be reassessed of all the complementary tests that have been requested.
Study NCT02377128 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral salpingectomy
Description: Surgical bilateral removal of fallopian tubes (not involving ovaries)
Study NCT02377128 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tubal ligation
Description: Bilateral ligation of fallopian tubes (not involving ovaries)
Study NCT01830907 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: carbohydrates
Study NCT01830907 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamins
Study NCT04421157 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Schroth Exercises
Description: The Schroth approach consists of 3D scoliosis-specific exercises based on kinesthetic and sensorimotor principles. The goal of Schroth exercises is to teach patients to consciously maintain the correct posture in daily living activities in order to improve the curve, pain, and self-image. The treatment program consists of scoliotic posture correction and a breathing pattern with the help of proprioceptive and exteroceptive stimulations and mirror control. Traditional exercises program included strengthening back, abdominal, pelvis and shoulder girdle muscles and also muscles in the convex side of the curve, stretching exercises especially for the concave side of the curve, postural training, flexibility exercises for the spine, and breathing exercises. Schroth group received Schroth exercises in addition to traditional rehabilitation for 10 weeks. Patients received 30 sessions for 90 minutes at the clinic for ten-week treatment period.
Study NCT04421157 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stabilization Exercises
Description: Each exercise session consisted of a warm-up exercise, core stabilization exercise, and a cool-down exercise. The core stabilization exercise was designed with consideration of local, global muscle stability training, global muscle mobility training,and strengthening training of these core structures was carried out progressively advancing more difficult. Traditional exercises program included strengthening back, abdominal, pelvis and shoulder girdle muscles and also muscles in the convex side of the curve, stretching exercises especially for the concave side of the curve, postural training, flexibility exercises for the spine, and breathing exercises. The Stabilization group received Core stabilization in addition to traditional rehabilitation for 10 weeks. Patients received 30 sessions for 90 minutes at the clinic for ten-week treatment period.
Study NCT04578509 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Nasopharyngeal swab
Description: Research of SARS-CoV-2 infection in nasopharyngeal swab by RT-PCR and by antigenic test
Study NCT04578509 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Saliva sample
Description: Research of SARS-CoV-2 infection in saliva samples by RT-PCR and by new detection approach
Study NCT04578509 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: axillary sweat sample
Description: Research of volatile olfactory compounds of SARS-CoV-2 infection by canine detection on axillary sweat.
Study NCT04578509 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Demographics, symptoms, medical history, acceptability of specimen, consumption in precedents hours are collected
Study NCT03937674 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HeartSteps: A just-in-time intervention for increasing physical activity among sedentary adults.
Description: HeartSteps is a smartphone based mHealth intervention that contains the following intervention components: (1) contextually-tailored suggestions for activity; (2) motivational messages aimed at keeping individuals motivated to be active; (3) planning of the next week's activity; and (4) adaptive weekly activity goals. Activity suggestions provide individuals with suggestions for how they can be active, and are tailored based on time of day, user's location, day of the week (weekend/weekday), and weather. Motivational messages are delivered to individuals via a push notification. Activity planning asks users to create a plan of how they will be active in the coming week. Participants are prompted to plan once a week. Each week, as part of the weekly planning, HeartSteps suggests an activity goal for the coming week based on their activity levels the previous week. Participants can edit the suggested goal, and the system-suggested goals top out at 150 minutes of activity per week.
Study NCT00662987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 7 days of amoxicillin
Description: Received 7 days of amoxicillin (dosed 40mg/kg divided bid up to maximum daily dose of 800 mg)
Study NCT00662987 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 3 days of amoxcillin followed by 4 days of placebo
Description: 3 days of amoxicillin (40 mg/kg divided bid up to maximum daily dose of 800 mg) followed by placebo
Study NCT01437371 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: - Angiotensin conversing enzyme inhibitors: enalapril, captopril, lisinopril, ramipril, trandolapril.
Description: The purpose of this study is to determine if there is an interest to optimize HF management in patients over 80 years old. The primary objective is to assess the effect of HF optimized management (guidelines of the European society of Cardiology (ESC) on QOL in aged over 80 year's old at 6 months
Study NCT01319487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2304 Eye Drops High Dose
Description: 2304 Eye Drops High Dose self-administered in the study eye during the treatment period
Study NCT01319487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2304 Eye Drops Low Dose
Description: 2304 Eye Drops Low Dose self-administered in the study eye during the treatment period
Study NCT01319487 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Eye Drops
Description: Placebo Eye Drops self-administered in the study eye during the treatment period
Study NCT01928199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Study NCT01928199 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04663932 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: immediate stenting group(one-step strategy)
Description: Patients assigned to the immediate stenting group will undergo appropriate stent implantation based on characteristics of the lesions.
Study NCT04663932 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: deferred stenting group (two-step strategy)
Description: Patients assigned to the deferred stenting group will be sent back to the ward after PCI to receive standard anticoagulant and antiplatelet therapies, and the CAG will be repeated 5 to 7 days after initial intervention, followed by treatment with stent implantation.
Study NCT06435078 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mPETS(modified-PETS system)
Description: The pressing evaluation and training system (PETS) consists of five force transducers, a pad position-adjustable frame, and biofeedback system. Five force transducers are used to collect the applied normal force from five digits.
Study NCT06435078 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mPETS(modified-PETS system)
Description: The pressing evaluation and training system (PETS) consists of five force transducers, a pad position-adjustable frame, and biofeedback system. Five force transducers are used to collect the applied normal force from five digits.
Study NCT01616758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTx-024 9mg
Study NCT02107313 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fed Cohort PBT2
Description: PBT2 250 mg is administered orally following a period of fasting for 10 hours and a high fat breakfast.
Study NCT02107313 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fasted Cohort PBT2
Description: PBT2 250 mg is administered orally after a period of fasting of 10 hours and without food
Study NCT00190398 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carotid angioplasty and stenting with cerebral protection
Description: Carotid angioplasty and stenting with cerebral protection
Study NCT01247389 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic colectomy
Description: Laparoscopic segmental colectomy with planned abdominal extraction site
Study NCT02315664 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education session, Fitbit Flex, and remote coaching by a PT
Description: Participants will receive a brief education session, use of a commercially available physical activity tracker called Fitbit Flex, and remote counseling by a PT. Intervention will be received immediately.
Study NCT02315664 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Same intervention with a 2 month delay
Description: The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 2 month delay.
Study NCT03479138 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Induced sputum
Description: Characterization with flow cytometry of the phenotype of the neutrophils isolated in the sputum, microbiome
Study NCT05208268 — intervention group
Intervention type: DRUG
Intervention: Pariet
Description: Pariet Tablets.
Study NCT01628692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: Capsule, oral, 150 mg, once daily
Study NCT01628692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablets, oral, 500-600 mg, twice daily
Study NCT03913169 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Educational Implementation of Interprofessional Curriculum
Description: The intervention utilized in this project will involve a 2-year curriculum. The year one/pre-clinical curriculum will be presented to pre-clinical doctor of osteopathic medical students (DO) and physician assistant students (PA) students. The year two/clinical curriculum will be presented to third year DO students and second year PA students once clinic sites are identified.
Study NCT01341249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental DW224aa
Description: DW224aa tablet, single dose
Study NCT01341249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Experimental DW224a
Description: DW224a capsule, single dose
Study NCT02757313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose THC marijuana
Study NCT02757313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose THC marijuana
Study NCT02757313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo marijuana
Study NCT02394652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin is an antidiabetic agent given orally.
Study NCT02394652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin is an antineoplastic agent given intravenously.
Study NCT02394652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin is an antineoplastic agent given intravenously.
Study NCT02394652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FAZA
Description: FAZA is an investigational imaging agent for positron emission tomography scans indicated for hypoxia.
Study NCT02394652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FAZA
Description: FAZA is an investigational imaging agent for positron emission tomography scans indicated for hypoxia.
Study NCT01684618 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cerebral NIRS Oximetry + CPAP
Description: CPAP flow pressure is increased for 5 minutes then 15 minutes with CPAP pressure at baseline. Repeated once
Study NCT03632083 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hy-Care Contact Lens Solution
Description: Hy-Care Contact Lens Solution
Study NCT03632083 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lite Contact Lens Solution
Description: Lite Contact Lens Solution
Study NCT03632083 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fanfilcon A soft contact lens
Description: fanfilcon A soft contact lens
Study NCT03632083 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A soft contact lens
Description: comfilcon A soft contact lens
Study NCT01087515 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood donation
Description: In experimental part 1 to generate preclinical data 250 ml of blood will be donated at day 1 by 10 subjects to induce allergen presenting cells (APCs).~In experimental part 2 to transfer the isolation of pDC or TREGs to a GMP (good manufacturing Practice) compliant clinical grade isolation system, leukapheresis will be performed with the blood from 5 subjects.~In experimental part 3 for potency testing of the clinical grade isolation system of pDC or TREGs, 250 ml of blood will be collected at day 1 from 3 subjects.
Study NCT05809336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inosine 0.2g orally 3 times/day
Description: inosine + PD-1/PD-L1 inhibitor ± chemotherapy/targeting,
Study NCT05809336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PD-1/PD-L1 inhibitor ,chemotherapy/targeting
Description: PD-1/PD-L1 inhibitor ± chemotherapy/targeting
Study NCT00927498 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional chemotherapy (AraC + Daunorubicin),
Description: Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3 Daunorubicin (DNR)first consolidation : 60 mg/m2 day 1. Daunorubicin (DNR)second consolidation : 60 mg/m2 day 1 and day 2.~Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7. Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4.
Study NCT00927498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mylotarg associated with conventional chemotherapy (AraC + Daunorubicin),
Description: Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3 Daunorubicin (DNR)first consolidation : 60 mg/m2 day 1. Daunorubicin (DNR)second consolidation : 60 mg/m2 day 1 and day 2.~Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7. Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4.~Mylotarg® (GO)induction : 3 mg/m2 IV (2 hours) Days 1, 4, 7. Mylotarg® (GO) First consolidation and Second Consolidation:3 mg/m2 day 1.
Study NCT04245345 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Accelerometer Sensing for Micra AV Study
Description: Characterize AV synchrony in subjects implanted with Micra AV device. The study will be conducted upon market approval of the Micra AV Transcatheter Pacing System.
Study NCT02472054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Study NCT02472054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methyl Prednisolone (MP)
Study NCT02472054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CSA)
Study NCT03552562 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Fourier Domain Color Doppler Optical Coherence Tomography (FDOCT)
Description: Fourier domain OCT is based on a local phase analysis of the backscattered signal and allows for bidirectional Doppler flow imaging.(Leitgeb et al. 2003a; Leitgeb et al. 2003b) It does not need reference arm scanning and records one full depth and Doppler profile in parallel. The system operates with an equivalent A-scan rate of 25 kHz and allows real time imaging of the color encoded Doppler information together with the tissue morphology at a rate of 2-4 tomograms (40 x 512 pixel) per second. Despite the high detection speed we achieve a system sensitivity of 86dB using a beam power of 500μW at the cornea. The fundus camera allows simultaneous view for selection of the region of interest. We observe bi-directional blood flow and pulsatility of blood velocity in retinal vessels with a Doppler detection bandwidth of 12.5 kHz and a longitudinal velocity sensitivity in tissue of 200μm/s. Diffuse luminance flicker will be applied during the measurements for 60 seconds.
Study NCT02872012 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoanesthesia device
Description: The study will be carried out in patients receiving bilateral injections. One eye will be anesthetized using the cryoanesthesia device, developed at the University of Michigan. This has been assessed to be a Non-significant Risk device.
Study NCT02872012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine applied to the non-cryoanesthesia eye.